Skip to main content
Devonian Health Group Inc logo

Devonian Health Group Inc — Investor Relations & Filings

Ticker · GSD ISIN · CA2518341078 TSXV Manufacturing
Open in API
Filings indexed 598 across all filing types
Latest filing 2023-01-09 Regulatory Filings
Country CA Canada
Listing TSXV GSD

About Devonian Health Group Inc

https://groupedevonian.com/

Devonian Health Group Inc. is a clinical-stage botanical pharmaceutical company specializing in the development of novel prescription therapeutic solutions for unmet medical needs. The core business involves late-stage prescription botanical drugs targeting fibroinflammatory autoimmune diseases, with a focus on gastrointestinal, dermatological, and hepatologic conditions. The company utilizes a broad-based technology platform, originating from over 20 years of research, to develop therapies that target multiple cellular pathways and regulate genes linked to these diseases. Its pipeline includes the lead product candidate, Thykamine, currently in Phase 3 clinical trials. Devonian also develops high-value dermatological products alongside its core drug development activities.

Recent filings

Filing Released Lang Actions
Notice of the meeting and record date - French.pdf
Regulatory Filings Classification · 95% confidence The document is a confirmation notice regarding the sending of the record date and meeting date notice for the annual and extraordinary meeting of security holders of Groupe Santé Devonian Inc. It includes details such as the meeting date (March 17, 2023), record dates for notice and voting (February 3, 2023), and information about the categories of shares entitled to vote. The document is short (2346 characters) and serves as a transmission confirmation rather than the actual meeting materials or results. It does not contain financial statements, voting results, or detailed meeting materials. Therefore, it is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement confirming the transmission of meeting notices to the relevant authorities and shareholders, not the meeting materials themselves or voting results.
2023-01-09 English
News release - English.pdf
Regulatory Filings
2023-01-06 English
Interim MD&A - French.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled "T1-2023 RAPPORT DE GESTION POUR LE TRIMESTRE TERMINÉ LE 31 OCTOBRE 2022" which translates to "Management Report for the quarter ended October 31, 2022." It provides a detailed overview of the company's activities, financial situation, research and development progress, and business objectives for the quarter. It includes substantive financial data and analysis for a period shorter than a full fiscal year (quarterly). The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement. The content matches the definition of an Interim / Quarterly Report (IR) as it covers a comprehensive financial report for a period shorter than a full fiscal year with actual financial and operational details. Therefore, the correct classification is IR (Interim / Quarterly Report). Q1 2023
2022-12-22 English
Interim MD&A - English.pdf
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Q1-2023 MANAGEMENT REPORT FOR THE THREE-MONTH PERIOD ENDED OCTOBER 31, 2022' and contains detailed discussion and analysis of the company's activities, financial position, research and development progress, and business objectives for the quarter. It includes substantive financial and operational data for a quarter period, consistent with a management report. The document is approximately 15,000 characters long, indicating it is a full report rather than a brief announcement or certification. The content aligns with the definition of a Management Report (MDA), which provides management's detailed explanation of financial results, business trends, and outlook for a period shorter than a full fiscal year. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q1 2023
2022-12-22 English
52-109F2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate signed by the CEO certifying the accuracy and fair presentation of the interim financial report and interim MD&A for the period ended October 31, 2022. It explicitly states it is a certification related to interim filings but does not contain the actual financial data or the interim report itself. The document is short (2998 characters) and serves as an officer certification rather than the interim report. According to the Certification Rule, such certifications should be classified as Regulatory Filings (RNS) rather than as the interim report (IR).
2022-12-22 English
Interim financial statements/report – French.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled "États financiers intermédiaires résumés consolidés" which translates to "Condensed Consolidated Interim Financial Statements" for the three-month period ended October 31, 2022. It contains detailed financial statements including consolidated statements of financial position, net income and comprehensive income, changes in equity, and notes. The document is unaudited and covers a quarterly period, which fits the definition of an Interim / Quarterly Report (IR). The length is substantial (15,000 characters), and it contains actual financial data and analysis, not just an announcement or certification. Therefore, the correct classification is IR (Interim / Quarterly Report). Q1 2023
2022-12-22 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.